<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695055</url>
  </required_header>
  <id_info>
    <org_study_id>Lym-SCT-001</org_study_id>
    <nct_id>NCT03695055</nct_id>
  </id_info>
  <brief_title>Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma</brief_title>
  <official_title>Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation in High-risk Aggressive Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging
      for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of
      maintenance therapy post-ASCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>High-risk Aggressive Lymphoma After Auto-HSCT</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DPP/DCEP-G alternation regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance therapy post-HSCT</intervention_name>
    <description>Rituximab vs DPP/DCEP-G vs observation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 14-70 years

          -  High-risk aggressive lymphoma underwent auto-HSCT

          -  Presence of 2 or more signs of unfavorable prognosis (IPI 2-4)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Adequate hematological function

          -  Offer informed consent

        Exclusion Criteria:

          -  Concomitant other cancer

          -  Congestive heart failure, unstable angina, severe cardiac arrhythmias and conduction
             disturbances, myocardial infarction

          -  Renal insufficiency (serum creatinine greater than 0.2 mmol/L) (except cases with
             specific kidney infiltration, urinary tract compression by tumor conglomerate or
             presence of uric acid nephropathy due to massive cytolysis syndrome)

          -  Liver failure (except cases with liver tumor infiltration), acute hepatitis or active
             phase of chronic hepatitis B or C with serum bilirubin greater than 1.5 standards,
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 3
             standards, prothrombin index less than 70%

          -  Severe pneumonia (except cases with specific lungs infiltration), accompanied by
             respiratory failure (dyspnea &gt; 30 in min., hypoxemia less than 70 mm Hg, when it is
             impossible to compensate situation in 2-3 days)

          -  Severe mental disorders (delusions, severe depressive syndrome and other
             manifestations of productive symptoms) not related with specific infiltration of
             central nervous system

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Yang, Prof.</last_name>
      <phone>+86-591-83357896</phone>
      <phone_ext>8041</phone_ext>
      <email>yang.hopeting@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianda Hu, Prof.</last_name>
      <phone>+86-591-83357896</phone>
      <phone_ext>8041</phone_ext>
      <email>jdhu@medmail.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ting Yang, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Ting YANG</investigator_full_name>
    <investigator_title>Prof.M.D.Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

